



Artificial Intelligence for Drug Discovery and Developments

Guest Editors:

Prof. Dr. Lei Wang

1. Big Data and Intelligent Computing Research Center, Guangxi Academy of Sciences, Nanning 530007, China
2. Xinjiang Technical Institutes of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, China

Prof. Dr. Zhu-Hong You

School of Computer Science, Northwestern Polytechnical University, Xi'an 710129, China

Deadline for manuscript submissions:
closed (31 October 2023)

Message from the Guest Editors

Dear Colleagues,

Intelligent computing technology has demonstrated its capabilities in almost all fields of science and engineering. The use of intelligent computing techniques to explore mechanisms in drug discovery and to draw meaningful conclusions is playing an increasingly important role in biology and medicine. Intelligent computational methods have shown their superior potential in drug target identification, drug repurposing, and drug molecular recombination, helping to solve problems such as drug design and disease diagnosis. Therefore, the use of intelligent computing techniques to analyze and interpret these data is becoming a hot topic in computational biology research. Therefore, we are organizing a Special Issue of *Biomedicines* entitled *Artificial Intelligence for Drug Discovery and Development* and are soliciting technical papers on drug discovery, proteomics, non-coding RNA association recognition, and bioinformatics through intelligent computing technologies. The purpose of this Special Issue is to present the latest research advances in the field of bioinformatics, and we welcome your contributions!





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI